Table 3.
Cumulative reduction in HPV-related disease incidence and cost for routine 9vHPV GNV with or without catch-up vaccination versus 9vHPV FOV in Hong Kong over 100 years (base case analysis).
| HPV-related disease | Number of cases averted (% reduction) versus 9vHPV FOV |
|
|---|---|---|
| Routine 9vHPV GNVa | Routine 9vHPV GNVa plus catch-up vaccinationb |
|
| Anal cancer (females) | 106 (4.6) | 167 (7.3) |
| Anal cancer (males) | 334 (14.6) | 390 (17) |
| Cervical cancer | 1,013 (4.5) | 1,818 (8.1) |
| CIN 1 | 182 (7.4) | 308 (12.5) |
| CIN 2/3 | 643 (6.9) | 1,090 (11.7) |
| Genital warts (females) | 38,982 (33.2) | 45,921 (39.1) |
| Genital warts (males) | 196,515 (51.1) | 210,691 (54.8) |
| Head and neck cancers (females) | 129 (4.8) | 197 (7.4) |
| Head and neck cancers (males) | 1,193 (16.2) | 1,370 (18.6) |
| HPV 6/11-related CIN 1 | 147 (30.9) | 168 (35.4) |
| Penile cancer | 569 (24.9) | 606 (26.5) |
| Vaginal cancer | 2 (3.2) | 5 (6.4) |
| VaIN 2/3 | 3 (3.9) | 5 (7.5) |
| Vulvar cancer | 5 (3.1) | 10 (6.3) |
| Total cost savings from reductions in cumulative incidence, 2019 HKD | $161,931,828 (4.3) | $242,362,835 (6.5) |
CIN, cervical intraepithelial neoplasia; FOV, female-only vaccination; GNV, gender-neutral vaccination; HKD, Hong Kong Dollar; HPV, human papillomavirus; VaIN, vaginal intraepithelial neoplasia.
a12-year-old girls and boys with 70% coverage.
b13- to 18-year-old females and males with 30% coverage.